ROCKLATAN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Rocklatan, and when can generic versions of Rocklatan launch?
Rocklatan is a drug marketed by Alcon Labs Inc and is included in one NDA. There are sixteen patents protecting this drug and one Paragraph IV challenge.
This drug has sixty-eight patent family members in fourteen countries.
The generic ingredient in ROCKLATAN is latanoprost; netarsudil dimesylate. There are twenty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the latanoprost; netarsudil dimesylate profile page.
DrugPatentWatch® Generic Entry Outlook for Rocklatan
Rocklatan was eligible for patent challenges on December 18, 2021.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 14, 2034. This may change due to patent challenges or generic licensing.
There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
Summary for ROCKLATAN
| International Patents: | 68 |
| US Patents: | 16 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 1 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for ROCKLATAN |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ROCKLATAN |
| What excipients (inactive ingredients) are in ROCKLATAN? | ROCKLATAN excipients list |
| DailyMed Link: | ROCKLATAN at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ROCKLATAN
Generic Entry Date for ROCKLATAN*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION/DROPS;OPHTHALMIC |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for ROCKLATAN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Aerie Pharmaceuticals | Phase 4 |
Pharmacology for ROCKLATAN
| Drug Class | Prostaglandin Analog Rho Kinase Inhibitor |
| Mechanism of Action | Rho Kinase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for ROCKLATAN
Paragraph IV (Patent) Challenges for ROCKLATAN
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| ROCKLATAN | Ophthalmic Solution | latanoprost; netarsudil dimesylate | 0.005%/0.02% | 208259 | 2 | 2021-12-20 |
US Patents and Regulatory Information for ROCKLATAN
ROCKLATAN is protected by sixteen US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of ROCKLATAN is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting ROCKLATAN
Dual mechanism inhibitors for the treatment of disease
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
Combination therapy
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
Dual mechanism inhibitors for the treatment of disease
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
Dual mechanism inhibitors for the treatment of disease
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
Compositions for treating glaucoma or reducing intraocular pressure
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Combination therapy
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
Dual mechanism inhibitors for the treatment of disease
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
Combination therapy
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Combination therapy
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
Combination therapy
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alcon Labs Inc | ROCKLATAN | latanoprost; netarsudil dimesylate | SOLUTION/DROPS;OPHTHALMIC | 208259-001 | Mar 12, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Alcon Labs Inc | ROCKLATAN | latanoprost; netarsudil dimesylate | SOLUTION/DROPS;OPHTHALMIC | 208259-001 | Mar 12, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Alcon Labs Inc | ROCKLATAN | latanoprost; netarsudil dimesylate | SOLUTION/DROPS;OPHTHALMIC | 208259-001 | Mar 12, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ROCKLATAN
When does loss-of-exclusivity occur for ROCKLATAN?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 14228790
Estimated Expiration: ⤷ Try a Trial
Patent: 18202965
Estimated Expiration: ⤷ Try a Trial
Patent: 18202990
Estimated Expiration: ⤷ Try a Trial
Patent: 20203976
Estimated Expiration: ⤷ Try a Trial
Canada
Patent: 05089
Estimated Expiration: ⤷ Try a Trial
China
Patent: 5263494
Estimated Expiration: ⤷ Try a Trial
Patent: 9528721
Estimated Expiration: ⤷ Try a Trial
Patent: 0396085
Estimated Expiration: ⤷ Try a Trial
Denmark
Patent: 11943
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 76080
Estimated Expiration: ⤷ Try a Trial
Patent: 61484
Estimated Expiration: ⤷ Try a Trial
Patent: 11943
Estimated Expiration: ⤷ Try a Trial
Patent: 18759
Estimated Expiration: ⤷ Try a Trial
Finland
Patent: 11943
Estimated Expiration: ⤷ Try a Trial
Hungary
Patent: 61618
Estimated Expiration: ⤷ Try a Trial
Japan
Patent: 16515520
Estimated Expiration: ⤷ Try a Trial
Patent: 19094339
Estimated Expiration: ⤷ Try a Trial
Patent: 20125355
Estimated Expiration: ⤷ Try a Trial
Patent: 20143163
Estimated Expiration: ⤷ Try a Trial
Patent: 21046439
Estimated Expiration: ⤷ Try a Trial
Patent: 23030072
Estimated Expiration: ⤷ Try a Trial
Netherlands
Patent: 1101
Estimated Expiration: ⤷ Try a Trial
Poland
Patent: 11943
Estimated Expiration: ⤷ Try a Trial
Portugal
Patent: 11943
Estimated Expiration: ⤷ Try a Trial
Spain
Patent: 76199
Estimated Expiration: ⤷ Try a Trial
Patent: 52377
Estimated Expiration: ⤷ Try a Trial
Patent: 42898
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering ROCKLATAN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | 2021046439 | 併用療法 (COMBINATION THERAPY) | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2010126626 | ⤷ Try a Trial | |
| Japan | 2012525442 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ROCKLATAN
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3461484 | 132021000000068 | Italy | ⤷ Try a Trial | PRODUCT NAME: COMBINAZIONE DI LATANOPROST E NETARSUDIL(ROCLANDA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1502, 20210108 |
| 3053913 | 132020000000043 | Italy | ⤷ Try a Trial | PRODUCT NAME: NETARSUDIL(RHOKIINSA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1400, 20191121 |
| 3461484 | 122021000036 | Germany | ⤷ Try a Trial | PRODUCT NAME: LATANOPROST, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, UND NETARSUDIL MESYLAT; REGISTRATION NO/DATE: EU/1/20/1502 20210107 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
